Lavender protects H9c2 cardiomyocytes against oxygen-glucose deprivation (OGD)-induced injury via targeting the JAK2/STAT3 pathway.
H9C2 cells
Inflammation
Ischemia/Reperfusion injury
JAK2/STAT3
Lavender oil
p-ERK/ERK
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
05
01
2021
accepted:
19
01
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
ppublish
Résumé
This study was conducted to examine the therapeutic effects of lavender oil (LO) against oxygen-glucose deprivation (OGD)-induced injury In this study, the OGD model was induced in the H9C2 cell line, and then the cells were treated with LO (10, 100, 1000, and 10000 μg/ml). The anti-inflammatory activity of LO (JAK2/STAT3) was evaluated by immunocytochemical assay. Likewise, the p-ERK/ERK level was measured by western blotting. Compared with only the OGD-induced injury model, cell survival increased after treatment with LO. Our results showed that 100 μg/ml of LO significantly decreased the expression of Jak2/Stat3 and the apoptotic activity 72 hr after reperfusion compared with the control group. Likewise, significant increases were observed in p-ERK/ERK in LO-treated groups. Collectively, these findings confirm that LO can be a good candidate to reduce OGD-induced injury in the H9C2 cell line through targeting Jak2/Stat3 and ERK pathways.
Identifiants
pubmed: 35655588
doi: 10.22038/IJBMS.2022.54751.12280
pmc: PMC9124541
doi:
Types de publication
Journal Article
Langues
eng
Pagination
263-267Déclaration de conflit d'intérêts
All authors declare that there are no conflicts of interest.
Références
BMC Cardiovasc Disord. 2011 Sep 29;11:57
pubmed: 21958326
Pharmacol Ther. 2008 Nov;120(2):172-85
pubmed: 18786563
Mol Med Rep. 2013 Jan;7(1):93-8
pubmed: 23128561
Circ Res. 2000 Mar 31;86(6):692-9
pubmed: 10747006
Front Pharmacol. 2019 Feb 12;10:61
pubmed: 30809145
Autophagy. 2015 Nov 2;11(11):2102-2113
pubmed: 26391455
Int J Clin Exp Pathol. 2015 Jan 01;8(1):466-73
pubmed: 25755735
J Clin Invest. 2013 Jan;123(1):92-100
pubmed: 23281415
J Biol Chem. 2008 Oct 24;283(43):29572-85
pubmed: 18723505
Cardiovasc Res. 2010 Aug 1;87(3):406-23
pubmed: 20448097
Food Chem Toxicol. 2009 Jul;47(7):1569-76
pubmed: 19362115
Front Pharmacol. 2020 Feb 18;11:64
pubmed: 32132924
Circulation. 2014 Apr 8;129(14):1493-501
pubmed: 24573351
Mol Med Rep. 2017 Dec;16(6):9309-9316
pubmed: 29039526
J Control Release. 2021 Feb 10;330:185-217
pubmed: 33340568
Biochem Biophys Res Commun. 2014 Aug 15;451(1):79-85
pubmed: 25063033
Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1433-40
pubmed: 14656708
Am J Cardiol. 2013 Mar 1;111(5):636-42
pubmed: 23273716
Int Immunopharmacol. 2020 Jul;84:106543
pubmed: 32353688
Mol Cell Biochem. 2013 Apr;376(1-2):175-88
pubmed: 23361363
Biochem Biophys Res Commun. 2019 Oct 1;517(4):697-702
pubmed: 31399192
Am J Cardiol. 2012 Sep 1;110(5):621-7
pubmed: 22608360
Basic Res Cardiol. 2008 Sep;103(5):444-53
pubmed: 18500485
Brain Res. 2014 Feb 22;1548:56-62
pubmed: 24384140
Front Neurol. 2019 Dec 05;10:1289
pubmed: 31920915
Front Pharmacol. 2017 Nov 14;8:819
pubmed: 29184499
Nat Prod Res. 2013;27(16):1497-501
pubmed: 22989360
Cell Cycle. 2020 Oct;19(20):2622-2630
pubmed: 32897801
Mol Cell Biochem. 2013 May;377(1-2):35-44
pubmed: 23378049